JP2023526677A5 - - Google Patents

Info

Publication number
JP2023526677A5
JP2023526677A5 JP2022571786A JP2022571786A JP2023526677A5 JP 2023526677 A5 JP2023526677 A5 JP 2023526677A5 JP 2022571786 A JP2022571786 A JP 2022571786A JP 2022571786 A JP2022571786 A JP 2022571786A JP 2023526677 A5 JP2023526677 A5 JP 2023526677A5
Authority
JP
Japan
Application number
JP2022571786A
Other languages
Japanese (ja)
Other versions
JP7677997B2 (ja
JP2023526677A (ja
JPWO2021237118A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033703 external-priority patent/WO2021237118A2/en
Publication of JP2023526677A publication Critical patent/JP2023526677A/ja
Publication of JPWO2021237118A5 publication Critical patent/JPWO2021237118A5/ja
Publication of JP2023526677A5 publication Critical patent/JP2023526677A5/ja
Application granted granted Critical
Publication of JP7677997B2 publication Critical patent/JP7677997B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022571786A 2020-05-22 2021-05-21 キナーゼターゲットエンゲージメントの増強 Active JP7677997B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063028729P 2020-05-22 2020-05-22
US63/028,729 2020-05-22
US202063109103P 2020-11-03 2020-11-03
US63/109,103 2020-11-03
PCT/US2021/033703 WO2021237118A2 (en) 2020-05-22 2021-05-21 Enhancement of kinase target engagement

Publications (4)

Publication Number Publication Date
JP2023526677A JP2023526677A (ja) 2023-06-22
JPWO2021237118A5 JPWO2021237118A5 (https=) 2024-05-28
JP2023526677A5 true JP2023526677A5 (https=) 2024-05-28
JP7677997B2 JP7677997B2 (ja) 2025-05-15

Family

ID=76959042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571786A Active JP7677997B2 (ja) 2020-05-22 2021-05-21 キナーゼターゲットエンゲージメントの増強

Country Status (4)

Country Link
US (2) US20210363565A1 (https=)
EP (1) EP4153770A2 (https=)
JP (1) JP7677997B2 (https=)
WO (1) WO2021237118A2 (https=)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US103A (en) 1836-12-10 Process
US8669A (en) 1852-01-20 John waters
US4812409A (en) 1986-01-31 1989-03-14 Eastman Kodak Company Hydrolyzable fluorescent substrates and analytical determinations using same
US4810636A (en) 1986-12-09 1989-03-07 Miles Inc. Chromogenic acridinone enzyme substrates
US5368484A (en) 1992-05-22 1994-11-29 Atari Games Corp. Vehicle simulator with realistic operating feedback
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
EP1594962B1 (en) 2003-01-31 2014-08-27 Promega Corporation Covalent tethering of functional groups to proteins
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
WO2007016975A1 (en) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
AR065015A1 (es) * 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
ES2795287T3 (es) 2009-05-01 2020-11-23 Promega Corp Luciferasas de Oplophorus sintéticas con mayor emisión de luz
SG10202103336SA (en) 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use
US20140099654A1 (en) 2012-09-26 2014-04-10 Promega Corporation Real-time monitoring
ES2926463T3 (es) 2013-03-15 2022-10-26 Promega Corp Activación de la bioluminiscencia mediante complementación estructural
WO2014176700A1 (en) * 2013-05-01 2014-11-06 Université de Montréal Biosensors for ras-dependent signaling pathways and use thereof
JP7092677B2 (ja) 2016-02-15 2022-06-28 プロメガ コーポレイション セレンテラジン類似体
JP7212612B2 (ja) 2016-07-28 2023-01-25 プロメガ コーポレイション セレンテラジン類縁体
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
US11442063B2 (en) * 2018-05-30 2022-09-13 Promega Corporation Broad spectrum kinase binding agents

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)